Astria Therapeutics (ATXS) Competitors $5.77 +0.04 (+0.77%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. OCUL, TVTX, BGM, GPCR, CVAC, CALT, DYN, AMPH, NAGE, and AUPHShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Ocular Therapeutix (OCUL), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), Niagen Bioscience (NAGE), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Its Competitors Ocular Therapeutix Travere Therapeutics BGM Group Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Dyne Therapeutics Amphastar Pharmaceuticals Niagen Bioscience Aurinia Pharmaceuticals Ocular Therapeutix (NASDAQ:OCUL) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Does the media favor OCUL or ATXS? In the previous week, Ocular Therapeutix had 3 more articles in the media than Astria Therapeutics. MarketBeat recorded 5 mentions for Ocular Therapeutix and 2 mentions for Astria Therapeutics. Astria Therapeutics' average media sentiment score of 0.93 beat Ocular Therapeutix's score of 0.79 indicating that Astria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, OCUL or ATXS? Ocular Therapeutix has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Do analysts recommend OCUL or ATXS? Ocular Therapeutix presently has a consensus target price of $17.33, suggesting a potential upside of 79.51%. Astria Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 419.57%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Astria Therapeutics is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do institutionals & insiders have more ownership in OCUL or ATXS? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 4.5% of Astria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, OCUL or ATXS? Astria Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M24.14-$193.51M-$1.15-8.40Astria TherapeuticsN/AN/A-$94.26M-$1.87-3.09 Is OCUL or ATXS more profitable? Astria Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. Astria Therapeutics' return on equity of -47.18% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-323.09% -59.92% -41.98% Astria Therapeutics N/A -47.18%-31.26% SummaryAstria Therapeutics beats Ocular Therapeutix on 11 of the 15 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$324.53M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-3.0821.2326.5720.02Price / SalesN/A280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book1.457.498.065.50Net Income-$94.26M-$55.05M$3.15B$248.50M7 Day Performance6.14%2.58%1.72%2.61%1 Month Performance16.41%5.22%3.92%5.42%1 Year Performance-35.84%5.04%35.02%20.76% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics1.8546 of 5 stars$5.77+0.8%$30.00+419.6%-36.1%$324.53MN/A-3.0830News CoverageOCULOcular Therapeutix3.8053 of 5 stars$8.37+3.0%$17.33+107.1%+41.6%$1.30B$63.72M-7.28230TVTXTravere Therapeutics3.2135 of 5 stars$14.49+1.3%$32.14+121.8%+83.4%$1.27B$273.53M-5.16460News CoverageAnalyst ForecastAnalyst RevisionBGMBGM GroupN/A$13.12+0.4%N/AN/A$1.27B$25.10M0.00298High Trading VolumeGPCRStructure Therapeutics2.7204 of 5 stars$22.10+1.7%$76.17+244.6%-47.2%$1.25BN/A-25.40136Gap UpHigh Trading VolumeCVACCureVac4.7052 of 5 stars$5.39-0.9%$9.00+67.0%+61.7%$1.22B$579.18M5.86880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180DYNDyne Therapeutics3.5118 of 5 stars$10.16-1.6%$43.93+332.4%-74.2%$1.17BN/A-2.83100AMPHAmphastar Pharmaceuticals4.2938 of 5 stars$24.68+0.5%$32.33+31.0%-37.3%$1.16B$731.97M8.942,028NAGENiagen Bioscience1.5124 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.06B$99.60M80.24120AUPHAurinia Pharmaceuticals2.7357 of 5 stars$7.83+0.8%$11.50+46.9%+37.9%$1.05B$235.13M27.96300 Related Companies and Tools Related Companies Ocular Therapeutix Competitors Travere Therapeutics Competitors BGM Group Competitors Structure Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Dyne Therapeutics Competitors Amphastar Pharmaceuticals Competitors Niagen Bioscience Competitors Aurinia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
